How a vitamin A derivative affects blood cell development in leukemia
Cellular and Molecular mechanisms of ATRA inhibition of osteoblast-induced MDS development
['FUNDING_R01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-10993084
This study is looking at how certain bone cells affect blood cell health and could lead to blood cancers like leukemia, and it’s testing a treatment called all-trans-retinoic acid to see if it can help improve conditions for patients with myelodysplastic syndromes and acute myeloid leukemia.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10993084 on ClinicalTrials.gov |
What this research studies
This research investigates the role of osteoblasts, which are bone cells that influence blood cell formation, in the development of myeloid malignancies like acute myeloid leukemia (AML). The study focuses on a specific signaling pathway involving beta-catenin that, when mutated, can lead to blood disorders. Researchers are exploring the effects of all-trans-retinoic acid (ATRA), a compound already used in treating certain leukemias, to see if it can inhibit this harmful signaling and improve blood cell health in patients with myelodysplastic syndromes (MDS) and AML. By understanding these mechanisms, the research aims to identify new treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes or acute myeloid leukemia who exhibit active beta-catenin signaling in their osteoblasts.
Not a fit: Patients without myelodysplastic syndromes or acute myeloid leukemia, or those not exhibiting the specific beta-catenin signaling mutation, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with myelodysplastic syndromes and acute myeloid leukemia.
How similar studies have performed: Previous studies have shown promising results with the use of ATRA in treating acute promyelocytic leukemia, suggesting potential for success in similar applications.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOUSTENI, STAVROULA — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: KOUSTENI, STAVROULA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.